CD274 and neoplasm: Results from CheckMate 358 indicate durable anti-tumor activity with first-line nivolumab and ipilimumab dual immunotherapy in patients with R/M CC patients, including those with PD-L1 expression on tumor cells of 1% or higher or less than 1% (12).